Bio Techne : Corporate Presentation – June 2025

Purposeful Innovation Leads

to Better Answers

Kim Kelderman

President s CEO

June 3, 2025

© 2025 Bio-Techne®. All rights reserved. | 1

© 2025 Bio-Techne®. All rights reserved. | 1

bi»techne" M‹Ssiox

We improve the quality of life by cataiyzingadvances in science and medicine.

© 2025 Bio-Techne®. All rights reserved. | 3

4 8 - Y E A R L E A D E R I N P R O T E O M I C S

Differentiated Portfolio Serving High-Growth Markets

Our Segments and Product Portfolio

Protein Sciences:

Proteins

Antibodies

Immunoassays

Proteomic Analytical Instruments

Cell Therapy

Diagnostics s Spatial Biology:

Spatial Biology

Precision Diagnostic Tools

Diagnostic Reagents s Controls

Instruments

Services

9% 9%

Royalties

2%

FY2024 Revenues

$1.2B

Instrument specific consumables

11%

Consumables

80%

© 2025 Bio-Techne®. All rights reserved. | 4

Headquarters

Minneapolis, MN

Number of Employees

~3,100

Worldwide Locations

34

FY2024 Revenues

~$1.2B

NASDAQ

TECH

Market Cap

~$8B

President s CEO

Kim Kelderman

Markets

12%

Distributors

50%

Pharma/ Biotech

17%

Diagnostics

21%

Academia

FY24 Revenue Breakdown ($1.2B)

Segments s Product End Markets

72%

Protein Sciences

Segment

28%

Diagnostics s Spatial

Biology Segment

10%

Core RUO Reagents s Assays*

6%

12%

42%

Spatial Biology

Precision Diagnostic Tools

Core Diagnostic Controls*

24%

Cell Therapy (GMP)

Proteomic Analytical Instruments

6%

Geographies

25%

EMEA

60%

Americas

9%

China

6%

APAC

*Core portfolio includes RUO Reagents, Assays s Diagnostic Controls (42% + 12% = 54%)

© 2025 Bio-Techne®. All rights reserved. | 5